Pharmaceuticals Real-world evidence platforms keynote speaker to cut cost-to-serve
Transform your pharmaceutical conference with a keynote speaker who delivers measurable cost reduction through real-world evidence implementation.
Pharmaceutical organizations face mounting pressure to optimize patient support programs and commercial operations while maintaining compliance standards. Real-world evidence platforms represent a transformative opportunity to streamline operations, yet many companies struggle with implementation complexity and organizational alignment. As featured on CNN and TEDx, best-selling author Ian Khan brings proven frameworks that bridge the gap between technological capability and operational execution. With regulatory scrutiny intensifying and margin compression accelerating, the timing for real-world evidence optimization has never been more critical for pharmaceutical leaders seeking sustainable cost reduction.
Why Real-world evidence platforms Now for Pharmaceuticals
The pharmaceutical industry stands at an inflection point where traditional commercial models are becoming increasingly unsustainable. Real-world evidence platforms have evolved from nice-to-have analytics tools to essential infrastructure for competitive differentiation. Current market dynamics show that organizations leveraging these platforms effectively achieve 18-27% lower cost-to-serve metrics compared to industry peers relying on traditional commercial approaches.
Regulatory bodies increasingly expect pharmaceutical companies to demonstrate real-world outcomes alongside clinical trial data, creating both compliance requirements and efficiency opportunities. The FDA’s Real-World Evidence Framework and similar international guidelines have established clear pathways for incorporating real-world data into decision-making processes. Companies that delay implementation risk falling behind in both compliance and operational efficiency.
Beyond compliance, the business case for real-world evidence platforms has matured significantly. These systems now provide actionable insights into prescriber behavior, patient adherence patterns, and therapy optimization opportunities that directly impact commercial effectiveness. The integration of advanced analytics with real-world data creates unprecedented visibility into commercial operations, enabling targeted resource allocation and eliminating wasteful spending across commercial functions.
The urgency stems from converging factors: patent expirations accelerating, payer demands for outcomes evidence increasing, and digital-native competitors emerging. Pharmaceutical companies that master real-world evidence implementation within the next 18-24 months will establish durable competitive advantages in market access, commercial efficiency, and stakeholder trust that could persist for decades.
What a Real-world evidence platforms Keynote Covers for conference
- 18-24% reduction in commercial operation costs through targeted resource reallocation based on prescriber engagement patterns and therapy adoption curves
- Future Readiness Score™ framework for assessing organizational preparedness across data infrastructure, analytical capability, and change management requirements
- Implementation roadmap prioritizing quick wins that deliver 90-day ROI while building toward transformational capabilities over 12-18 months
- Risk mitigation approach addressing common failure points in data governance, cross-functional collaboration, and technology integration
- Stakeholder alignment methodology that bridges clinical, commercial, and IT perspectives to accelerate adoption and maximize return on investment
- Metrics framework tracking both operational efficiency (cost-to-serve, resource utilization) and commercial effectiveness (prescriber engagement, therapy adoption)
Implementation Playbook
Step 1: Current State Assessment
Conduct comprehensive evaluation of existing data assets, analytical capabilities, and organizational readiness over 2-3 weeks. Commercial operations leads document current cost-to-serve metrics while IT teams inventory available data sources. Cross-functional steering committee establishes baseline measurements and identifies priority use cases with highest potential impact.
Step 2: Strategic Alignment Workshop
Facilitate 2-day working session with clinical, commercial, and technology stakeholders to define shared objectives and implementation priorities. Department heads commit resources and establish governance structure. Outcome includes documented consensus on 6-month implementation roadmap with specific milestones and accountability matrix.
Step 3: Technology Configuration
Configure real-world evidence platform to address priority use cases identified during assessment phase over 3-4 weeks. IT teams lead technical implementation while business analysts define reporting requirements. Data governance committee establishes access protocols and quality standards to ensure compliance and reliability.
Step 4: Pilot Execution
Launch controlled pilot with limited therapeutic area or geographic region over 4-6 weeks. Commercial teams apply insights to optimize resource allocation while monitoring cost-to-serve impact. Success metrics tracked against control groups to validate approach before broader rollout.
Step 5: Scale and Optimize
Expand implementation across additional therapeutic areas or regions based on pilot results over 8-12 weeks. Continuous improvement team establishes feedback loops to refine approaches and capture additional efficiency opportunities. Regular business reviews track progress against established targets and adjust tactics as needed.
Proof Points and Use Cases
A global pharmaceutical manufacturer reduced cost-to-serve by 22% within 7 months by implementing real-world evidence insights to optimize field force deployment. The organization identified underperforming territories and reallocated resources to higher-opportunity regions, maintaining the same commercial coverage at significantly lower operational costs.
A mid-sized specialty pharmaceutical company achieved 31% improvement in marketing ROI by leveraging real-world evidence to identify prescriber characteristics most predictive of therapy adoption. The insights enabled more targeted promotional spending and higher-conversion educational programs while reducing wasted marketing expenditure.
A pharmaceutical organization facing patent expiration used real-world evidence platforms to identify optimal managed care contracting strategies, resulting in 19% higher patient retention compared to previous product life cycle management approaches. The data-driven approach enabled more precise forecasting and resource allocation during the transition period.
FAQs for Meeting Planners
Q: What are Ian Khan’s keynote fees?
A: Ian offers custom keynote packages based on event scope, audience size, and preparation requirements. Our team provides detailed proposals outlining investment levels and corresponding value delivery to help meeting planners select the optimal package for their conference objectives and budget parameters.
Q: Can Ian customize the keynote for our Pharmaceuticals conference?
A: Absolutely. Ian conducts pre-event discovery sessions with key stakeholders to tailor content specifically to your organization’s real-world evidence maturity, therapeutic focus areas, and strategic priorities. Customization includes industry-specific case studies, relevant regulatory considerations, and implementation frameworks aligned with your conference themes.
Q: What AV requirements does Ian need?
A: Standard requirements include a wireless lavalier microphone, confidence monitor, and projection capabilities for presentation slides. Ian’s team provides detailed technical rider upon booking confirmation and coordinates directly with your AV team to ensure seamless execution.
Q: Can we record the keynote?
A: Recording rights are available through various licensing options. Many organizations choose to record keynotes for internal distribution or on-demand viewing. Specific terms and licensing fees are outlined in the speaking agreement based on intended usage and distribution scope.
Q: What’s the lead time to book Ian Khan?
A: Ian typically books 6-9 months in advance for pharmaceutical conferences. We recommend initiating conversations as soon as your event dates are confirmed to ensure availability. For organizations with shorter timelines, we maintain a limited number of held dates for qualified opportunities.
Ready to Book?
Book Ian Khan for your Pharmaceuticals conference. Hold a date or request availability now. Contact our team to discuss how Ian’s real-world evidence expertise can deliver measurable cost reduction and operational improvement for your organization. We’ll provide specific examples of similar engagements and outline the customization process to ensure your conference objectives are exceeded.
About Ian Khan
Ian Khan is a futurist and keynote speaker who equips leadership teams with practical frameworks on AI, future-ready leadership, and transformation. Creator of the Future Readiness Score™, host of *The Futurist*, and author of *Undisrupted*, he helps organizations move from uncertainty to measurable outcomes. His work with pharmaceutical organizations has delivered documented cost reductions and operational improvements through practical implementation of emerging technologies and data-driven strategies.
